Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Rituximab and brentuximab vedotin with deferred BMT for relapsed classical Hodgkin lymphoma
Johns Hopkins Kimmel Cancer Center in Baltimore
This study investigates a new combination of drugs for treating a first relapse of Hodgkin lymphoma. Rituximab, an antibody drug for non-Hodgkin lymphomas, might attack the â??cancer stem cellâ?? that causes Hodgkin lymphoma. This study adds rituximab to another drug, brentuximab vedotin, which targets Hodgkin/Reed-Sternberg cells. The goal is to try to kill â??cancer stem cellsâ?? as well as the other cancer cells, so that people might avoid riskier treatments like a stem cell transplant.
To join the study, you must be at least 16 years old, have a first relapse of classical Hodgkin lymphoma (Hodgkin disease), and never have had rituximab or brentuximab vedotin (Adcentris).
Treatment involves up to 8 doses of brentuximab, and up to 10 doses of rituximab. This treatment schedule may change depending on how you are doing: Brentuximab will be given Day 1 of each 21 day (3 week) cycle, for up to 8 cycles. You will first receive brentuximab on Day 1of Cycle 1 and Day 1 of Cycle 2. A PET/CT scan will then be repeated, to see if your lymphoma has decreased. If your lymphoma has decreased enough (either a partial or complete remission) after the first two doses, you will continue with the study treatment; otherwise you will be taken off study. If you continue with the study treatment, brentuximab will continue to be given at the beginning of each cycle (or every 3 weeks) for a total of up to 8 cycles, and also, Rituximab will begin on Day 1 of Cycle 3. The rituximab will be given weekly for 4 weeks, then every three weeks for 4 doses. Then, additional (maintenance) dose of rituximab will be given once every 3 months for two doses.
01/18/2017 05:03 AM